Katsumi Morishita
Otsuka Pharmaceutical
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Katsumi Morishita.
Toxicology | 2001
Katsumi Morishita; Hiroshi Okumura; Norio Ito; Nobuo Takahashi
The present study was conducted to confirm the usefulness of a primary culture system of adrenocortical cells from dogs for detecting the direct effects of the chemicals on adrenal cortex. Corticosteroid levels in the culture supernatant were measured using high-performance liquid chromatography (HPLC) following 24-h incubation with the chemicals. Ketoconazole, miconazole, metyrapone, aminoglutethimide, and 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p-DDD), which were known to inhibit cortisol production were evaluated in this system. Both viable cells and corticosteroid levels were decreased by o,p-DDD treatment. Other chemicals showed various inhibition patterns of corticosteroid levels as follows without affecting cell viability. Ketoconazole decreased total corticosteroids level by mainly due to the decreases in cortisol and 11-deoxycortisol levels. Miconazole decreased cortisol and 11-deoxycortisol levels, however, slightly increased corticosterone level. Metyrapone decreased cortisol and corticosterone levels as 11-deoxycortisol and 11-deoxycorticosterone levels were increased. Aminoglutethimide decreased total corticosteroids level by mainly decreasing cortisol, corticosterone and 11-deoxycortisol levels. These results suggested that determination of the pattern of corticosteroid levels by HPLC in this system well reflected the mode of their action on steroidogenesis. Thus, we conclude this simple system was useful to determine the direct effects of chemicals on steroidogenesis in the adrenal cortex.
International Journal of Toxicology | 2015
Yuichi Shimomura; William J. Brock; Yuko Ito; Katsumi Morishita
PCK rats develop age-related polycystic kidney disease (PKD) and liver disease and have been used to investigate pharmacotherapies to ameliorate hepatorenal lesions for patients with PKD. The PCK rat may be useful to understand the possible susceptibility to hepatotoxicity observed in the patient with PKD having hepatic polycystic lesions. Therefore, the purpose of this study was to investigate the background blood biochemical changes that reflect the hepatorenal function of PCK rats as well as the terminal histopathology in order to determine whether this model would be suitable for extrapolating the susceptibility of hepatotoxicity in patients. The blood biochemical parameters of hepatorenal function and histopathology were investigated in PCK rats at ages 5 to 19 weeks and compared to those outcomes in the Sprague Dawley (SD) rat. There were notable blood biochemical changes possibly due to biliary dysgenesis in the PCK rat as early as 5 weeks of age. High levels of γ-glutamyl transpeptidase, alkaline phosphatase, alanine aminotransferase, and total bile acids persisted throughout the study compared to the SD rat. Increased aspartate aminotransferase, total bilirubin, and hyperlipidemia and a decrease in albumin were also evident at 10 to 19 weeks of age possibly due to progression of cholestatic liver dysfunction secondary to age-related liver cystic progression. Increased liver weights generally correlated with the severity of biliary and hepatic histopathological changes. In male PCK rats, age-related increases in blood urea nitrogen and creatinine at 10 to 19 weeks of age were observed, and the cystic progression was more severe than that in females. These data indicate that the PCK rat showed notable blood biochemical changes reflecting alteration of the liver function compared to the SD rat. Also, there was a large individual variation in these parameters possibly due to variable progression rate of biliary dysgenesis and subsequent liver damages in PCK rats.
Journal of Toxicological Sciences | 2006
Katsumi Morishita; Yumiko Mizukawa; Toshihiko Kasahara; Manabu Okuyama; Kayoko Takashima; Naoki Toritsuka; Toshikazu Miyagishima; Taku Nagao; Tetsuro Urushidani
Life Sciences | 2006
Kayoko Takashima; Yumiko Mizukawa; Katsumi Morishita; Manabu Okuyama; Toshihiko Kasahara; Naoki Toritsuka; Toshikazu Miyagishima; Taku Nagao; Tetsuro Urushidani
Cardiovascular Drugs and Therapy | 2011
Akihide Oi; Katsumi Morishita; Takumi Awogi; Atsushi Ozaki; Masanao Umezato; Shinji Fujita; Eiji Hosoki; Hajime Morimoto; Nobuya Ishiharada; Hironobu Ishiyama; Tohru Uesugi; Masaya Miyatake; Tadashi Senba; Toshiyuki Shiragiku; Naoto Nakagiri; Norio Ito
日本トキシコロジー学会学術年会 第37回日本トキシコロジー学会学術年会 | 2010
Kaori Abe-Tomizawa; Yohsuke Minowa; Katsumi Morishita; H. Yamada; Tetsuro Urushidani; Yasuo Ohno
Journal of Toxicological Sciences | 2005
Hirohiko Goto; Tadashi Senba; Yuichi Shimomura; Nobuya Ishiharada; Tomonori Tahara; Katsumi Morishita
Journal of Toxicological Sciences | 2004
Naoki Toritsuka; Toshihiko Kasahara; Katsumi Morishita; Manabu Okuyama; Kayoko Takashima; Takayoshi Suzuki; Toshikazu Miyagishima; Tetsuro Urushidani; Taku Nagao
Journal of Toxicological Sciences | 2004
Kayoko Takashima; Katsumi Morishita; Manabu Okuyama; Toshihiko Kasahara; Naoki Toritsuka; Toshikazu Miyagishima; Tetsuro Urushidani; Taku Nagao
Journal of Toxicological Sciences | 2004
Katsumi Morishita; Toshihiko Kasahara; Manabu Okuyama; Kayoko Takashima; Naoki Torituka; Toshikazu Miyagishima; Tetsuro Urushidani; Taku Nagao